MK0524A Phase IIb Study (0524A-011)(COMPLETED)

PHASE2CompletedINTERVENTIONAL

Enrollment

154

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

February 28, 2005

Study Completion Date

December 31, 2006

Conditions

Flushing

Interventions

DRUG

Comparator: niacin / Duration of Treatment: 17 Weeks

DRUG

MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks

DRUG

Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00536237 - MK0524A Phase IIb Study (0524A-011)(COMPLETED) | Biotech Hunter | Biotech Hunter